Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
531 Results for "
PD+1
" in MedChemExpress (MCE) Product Catalog:
Products (531)
531 Results for "PD+1" in MCE Product Catalog:
35
35 Publications Verification
Art. -Nr.: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
Target:
Forschungsgebiete:
35
35 Publications Verification
Art. -Nr.: HY-P9902
CAS. Nr.: 1374853-91-4
Synonyms: MK-3475; Lambrolizumab
Target:
Forschungsgebiete:
35
35 Publications Verification
Target:
Forschungsgebiete:
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models [1] .
32
Target:
Forschungsgebiete:
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1] .
27
27 Cited Publications
Art. -Nr.: HY-P99144
Target:
Forschungsgebiete:
26
26 Cited Publications
Art. -Nr.: HY-19745
CAS. Nr.: 1675203-84-5
Target:
Forschungsgebiete:
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity [1] .
26
26 Cited Publications
Art. -Nr.: HY-19745B
CAS. Nr.: 2089334-95-0
Target:
Forschungsgebiete:
BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity [1] .
24
24 Cited Publications
Art. -Nr.: HY-P9903
CAS. Nr.: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106
Target:
19
19 Cited Publications
Art. -Nr.: HY-P99145
Target:
Forschungsgebiete:
9
9 Cited Publications
Target:
Forschungsgebiete:
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .
9
9 Cited Publications
Target:
Forschungsgebiete:
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .
6
6 Cited Publications
Target:
Forschungsgebiete:
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
6 Cited Publications
Target:
Forschungsgebiete:
BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
Target:
Forschungsgebiete:
6
Target:
Forschungsgebiete:
6
Forschungsgebiete:
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
5
5 Cited Publications
Art. -Nr.: HY-P990679
Target:
Forschungsgebiete:
4
Target:
Forschungsgebiete:
4
4 Cited Publications
Art. -Nr.: HY-P81169A
Synonyms: Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; Systemic lupus erythematosus susceptibility 2.
3
3 Cited Publications
Art. -Nr.: HY-P990824
Target:
Forschungsgebiete:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
